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Simple Summary: More than 50% of breast cancer (BC) patients selected for neoadjuvant chemother-
apy (NACT) are subjected to at least a 6-month regimen of this treatment without a clear benefit,
probably delaying more effective therapeutic strategies and being exposed to potential treatment-
associated toxicity. Thus, it is urgent to implement reliable predictive biomarkers, as well as novel
treatments for NACT non-responder patients. This study validates that the HLA-DR level in cytotoxic
T lymphocytes (CTLs) is an independent and robust predictive factor of BC patients’ response to
NACT, as previously proposed. Hence, a predictive probability model of response was developed as
a new tool to improve treatment decisions. HLA-DR level in CTLs also have a general prognostic
value, which might be relevant for long-term BC management. In addition, our results suggest that
increasing the expression of HLA-DR in CTLs of non-responders could be a promising therapeutic
strategy to ameliorate BC response to NACT.
Abstract: Neoadjuvant chemotherapy (NACT) is common in breast cancer (BC) treatment, though
more than half of the patients lack an effective response. Therefore, new predictive biomarkers and
alternative therapies are crucial. Previously, we proposed HLA-DR-expressing cytotoxic T lym-
phocytes (CTLs) as a potential biomarker of the response to NACT. To validate this observation
and further investigate these cells, 202 BC patients were enrolled. Flow cytometry analyses were
performed in 61 biopsies and 41 blood samples pre-NACT and 100 non-NACT tumor samples. All
the patients were followed up for 34 months. Blood-isolated immune cells were cultured with BC
cell lines in a 3D system. We confirmed that HLA-DR level in CTLs is a highly sensitive, specific, and
independent biomarker to predict response to NACT and developed a predictive probability model.
This biomarker was also associated with progression-free survival, regardless of the treatment. The
clinical observations are substantiated by the anti-tumor properties of HLA-DR-expressing CTLs.
Intriguingly, HLA-DR level in CTLs can be modulated ex vivo, boosting their capacity to kill tumor
cells synergistically with doxorubicin. Thus, HLA-DR expression in CTLs is a validated tool to
select patients that will actually benefit from NACT, and its stimulation might be a novel therapeutic
approach for BC.
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1. Introduction
Breast cancer (BC) is the most frequent type of cancer in women worldwide, account-
ing for up to two million new cases per year [1]. Early-stage disease has a high 5-year
survival rate, with 99% for estrogen receptor positive (ER+) tumors, 94% for human epider-
mal growth factor receptor 2 (HER2+) overexpressing tumors, and 85% for triple negative
breast cancer (TNBC) [2]. Nevertheless, when the disease is in an advanced stage, the
survival rate is lower, probably due to the lack of effective specific treatment options [2].
Indeed, independently of the BC subtype, the treatment option for locally advanced BC is
neoadjuvant chemotherapy (NACT). Although NACT is important in downstaging the
tumor, allowing a breast-conserving surgery [3], approximately half of the patients do not
respond to this treatment [4,5]. Thus, it is essential to find biomarkers of response to NACT,
as well as alternative therapeutic options for non-responders.
NACT efficacy may depend on immune players present in the tumor microenviron-
ment, namely, tumor-infiltrating lymphocytes (TILs) and, as such, TILs have been studied
as possible biomarkers to predict response to NACT. Actually, chemotherapy promotes
immunogenic cell death (ICD), which involves the release of damage-associated molecular
patterns (DAMPs) by dying cells that might lead to the activation of particular TILs (namely
cytotoxic T lymphocytes—CTLs) that, in turn, will allow the control of NACT-resistant
tumor cells [6]. However, accumulating evidence has been shown that the same ICD-
resulting DAMPs could, in certain conditions, support cancer progression and resistance to
treatment [7]. Additionally, tumors have several mechanisms to escape immune surveil-
lance and TILs-mediated killing [8]. Hence, quantification of TILs is still not used routinely
in the clinical setting.
We have previously reported that CTLs expressing high levels of the activation marker
HLA-DR in fresh BC biopsies were a highly sensitive and specific factor to predict re-
sponse to NACT [9]. In this preceding study, we found that HLA-DR+ CTLs were mainly
present inside the tumor microenvironment; produced high levels of cytotoxicity-related
molecules, such as IFN-γ, Granzyme B, and Perforin; were negatively correlated with
immunosuppressive features of the tumor milieu; and were reflected systemically [9].
HLA-DR (human leukocyte antigen) is a class II MHC molecule, normally expressed
in professional antigen presenting cells. Nonetheless, in lymphocytes, namely in CTLs, it is
a late-phase activation marker, being upregulated 24/48 h after the activation of these cells,
and it is associated with increased IFN-γ production. It is preceded by an increase in the
expression of CD69 and CD25, which are upregulated 4 h and 12 h after T cell activation,
respectively [10–14].
HLA-DR expression on effector T lymphocytes upon their activation has been in-
tensively described in some diseases, such as auto-immune diseases and viral infec-
tions [15–17]. The increase of HLA-DR at CTLs’ surface, upon stimulation, could also
be required to boost an effective immune response. Indeed, HLA-DR+ CTLs were found
to have the machinery needed for antigen processing and loading on HLA-DR molecules
and, additionally, could express CD86 and CD80, which are the co-stimulatory molecules
of antigen presenting cells that are necessary for the proper T cell effector function [18].
Moreover, it was described that T cell–T cell synapsis occurs to allow T cells to secrete IFN-γ
towards each other, compelling the differentiation of more protective T cells [19]. These T
cell–T cell interactions and mutual antigen presentation can be essential for mounting a
suitable anti-tumor response.
In order to confirm HLA-DR-expressing CTLs as a biomarker of response to NACT,
following the REMARK (reporting recommendations for tumor marker prognostic studies)
criteria [20], we conducted a validation study in an independent cohort of BC patients,
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tackling one of the clinical needs in BC management. Moreover, we took advantage of a
3D co-culture platform of BC cell lines and patient-derived immune cells, developed to be
used in the future as a drug screening platform [21], to shed some light on the anti-tumor
role of HLA-DR+ CTLs and further explore their potential therapeutic value.
Thus, here we validate HLA-DR level in CTLs as a new, independent biomarker to
predict BC response to NACT and, additionally, as a general BC prognosis factor. Likewise,
we suggest that the modulation of HLA-DR expression in CTLs could be an interesting
approach to ameliorate advanced BC treatment and, therefore, the survival rates of this
disease.
2. Materials and Methods
2.1. Patients’ Samples
This prospective study was designed following the REMARK criteria [20]. A total of
202 breast cancer (BC) patients were enrolled in this study (Figure 1). Sixty-one fresh biop-
sies (from a previous pilot cohort and from this validation cohort) of BC patients selected
for neoadjuvant chemotherapy (NACT) were collected in Transfix (Cytomark, Buckingham,
UK) to preserve cellular antigens. NACT was composed of four cycles of doxorubicin
and cyclophosphamide every 3 weeks, followed by 12 weeks of paclitaxel. Trastuzumab
was given every 3 weeks to HER2+ patients. A summary of the patients’ characteristics
is presented in Table 1. The biopsies were mechanically dissociated with a BD Medicon
(BD Biosciences, Franklin Lakes, NJ, USA), filtered through a 30 µm mesh (Sysmex, Kōbe,
Japan), washed with PBS1X, and stained for flow cytometry (as described below). Biopsies
and surgical specimens from non-NACT patients were similarly handled and were used,
together with NACT samples, in the progression-free survival analysis. Forty-one blood
samples were collected from non-matched BC patients selected for NACT in Vacutainer
tubes with EDTA (BD Biosciences, Franklin Lakes, NJ, USA). Whole blood staining for
flow cytometry was performed as described below. Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood by a Ficol gradient (Merck Millipore, Burlington,
VT, USA) and cryopreserved in 90% fetal bovine serum (FBS, Biowest, Riverside, CA,
USA) and 10% dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO, USA) to be used
later in the 3D co-culture systems. Isolated PBMCs from eight healthy donors’ buffy coats
provided by Instituto Português do Sangue e da Transplantação were used specifically in
the cytotoxicity assay.







Figure 1. Flowchart of patients enrolled in this study. Breast cancer patients (n = 202) were divided according to the 
prescription of neoadjuvant chemotherapy (NACT). The biopsies of NACT patients were divided into two different 
cohorts for the predictive biomarker study. Blood samples were also used in this study and to isolate PBMCs for in vitro 
3D co-culture assay. Progression-free survival (PFS) was performed for NACT and non-NACT patients. 
Table 1. Characteristics of patients enrolled in this study (median values of age, body mass index, and percentage of post-
menopause patients). Clinical data, such as subtype of breast cancer, grade, median of Ki67, and of tumor dimension and 
node status, are also described. 
Characteristics  
1st Cohort 2nd Cohort 
Responders (n = 13) Non-responders (n = 17) Responders (n = 11) Non-responders (n = 20) 
Age (median + range) 57 (39–82) 64 (45–79) 47.5 (29–67) 58 (39–71) 
Figure 1. Flowchart of patients enrolled in this study. Breast cancer patients (n = 202) were divided according to the
prescription of neoadjuv nt chemotherapy (NACT). The biopsies of NACT patients were divide into two different cohorts
for the predictive biomarker study. Blood samples were also used in this study and to isolate PBMCs for in vitro 3D
co-culture assay. Progression-free survival (PFS) was performed for NACT and non-NACT patients.
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Table 1. Characteristics of patients enrolled in this study (median values of age, body mass index, and percentage of
post-menopause patients). Clinical data, such as subtype of breast cancer, grade, median of Ki67, and of tumor dimension
and node status, are also described.
Characteristics
1st Cohort 2nd Cohort
Responders (n = 13) Non-Responders (n = 17) Responders (n = 11) Non-Responders (n = 20)
Age (median + range) 57 (39–82) 64 (45–79) 47.5 (29–67) 58 (39–71)
Body mass index
(median + range) 25.31 (22.04–32.03) 25.39 (22.07–33.2) 32.05 (20.51–46.64) 28.01 (19.36–39.73)
Post-menopause 76.92% 58.82% 45.45% 77.78%
ER+ (PR –/+) 30.77% 41.18% 11.12% 47.37%
HER2+ including triple
positive breast cancer 38.46% 17.64% 44.44% 42.10%
TNBC 30.77% 41.18% 44.44% 10.53%
Grade
G1—15.38% G1—0% G1—25% G1—17.65%
G2—30.77% G2—47.06% G2—37.5% G2—47.06%
G3—53.85% G3—52.94% G3—37.5% G3—35.29%
Ki67 (median + range) 47.40% (15–97) 19.15% (2–80) 40% (10–75) 40% (5–90)
Tumor dimension in
mm (median + range) 38 (19–63) 25 (10–70) 29.5 (7–65) 25 (9–80)
Axillary lymph node
invasion status
Negative—38.46% Negative—35.29% Negative—44.44% Negative—23.53%
Positive—61.54% Positive—64.71% Positive—55.56% Positive—76.47%
Samples were gathered from Hospital CUF Descobertas, Hospital de Vila Franca de
Xira, Hospital Prof. Doutor Fernando Fonseca, and Hospital Santa Maria. For each patient,
written informed consent and approval by the ethical committees of the hospitals and of
the NOVA Medical School (97/2019/CEFCM) were obtained.
2.2. Flow Cytometry
Cell suspension from the processed BC samples was stained with a cocktail of mouse
anti-human surface antibodies for 15 min. The cells were then fixed and permeabilized
with Fix/Perm kit (Invitrogen, Waltham, MA, USA), followed by intracellular staining for
30 min. In case of whole blood, the staining protocol was similar, but it was followed by a
step of red blood cells lysis with RBC lysis buffer (Biolegend, San Diego, CA, USA). Data
were acquired in BD FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA), and the
results were analyzed using FlowJo software v10. The data are presented as a percentage of
the populations with respect to the single cells’ gate (Figure S1). To analyze the expression
levels of HLA-DR in cytotoxic T lymphocytes (CTLs), we considered the median fluorescent
intensity (MFI) (arbitrary units from the FACS) of the positive population and normalized
it to the MFI of the negative population, as we previously described [9]. The negative
population was superimposed with the unstained control. For the characterization of
HLA-DR+ CTLs (Section 3.3.), we have quantified the percentage of each marker gated
inside HLA-DR+ CTLs (Figure S1) and normalized it to the percentage of the same marker
in HLA-DR negative CTLs to decrease variability between samples.
The monoclonal mouse anti-human antibodies used were: anti-CD45-PercP, anti-CD3-
APC, anti-CD19-PE, anti-CD15-PE, anti-CD161-FITC, anti-CD4-FITC, anti-CD8-PE, anti-
HLA-DR-APC, anti-CD127-PE-Cy7, anti-CD25-PE, anti-CD163-PE, anti-CD206-APC-Cy7,
anti-PD-L1-APC, anti-CD11b-FITC, anti-IL-10-FITC, anti-CD69-PercP, anti-IFN-γ-APC-
Cy7, anti-GranzymeB-FITC, anti-Ki67-PE, anti-CD45RO-PercP, anti-PD-1-FITC, anti-Tim3-
APC-Cy7, anti-CD39-BV421 (Biolegend, San Diego, CA< USA), and anti-CD103-PE-Cy7
(Invitrogen, Waltham, MA, USA).
2.3. Fluorescence Activated Cell Sorting (FACS)
PBMCs from healthy donors were cultured overnight in RPMI-1640 (Gibco, Waltham,
MA, USA) supplemented with 10% FBS and 1% Penicillin/Streptomycin (GE Healthcare,
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Chicago, IL, USA) and stimulated with 35 ng/mL of phorbol 12-myristate 13-acetate
(PMA, Sigma Aldrich, St. Louis, CA, USA) and 1 µg/mL of ionomycin (Merck Millipore,
Burlington, VT, USA) at 37 ◦C, 5% CO2. Cells were then stained with BD Horizon™ Fixable
Viability Stain 450 (BD Biosciences, Franklin Lakes, NJ, USA) for 20 min in ice, followed by
staining with the antibodies anti-CD45-PercP, anti-CD8-PE, and anti-HLA-DR-APC. Cells
were sorted into two populations: CD45+/CD8+/HLA-DR+ and CD45+/CD8+/HLA-
DRnegative in a FACS Aria III (BD Biosciences, Franklin Lakes, NJ, USA) with an efficiency
above 90%.
2.4. Cytotoxicity Assays in 3D Co-Cultures
The BC cell lines MCF-7 and MDA-MB-231 were cultured in DMEM (Biowest, River-
side, CA, USA) supplemented with 10% FBS and 1% Penicillin/Streptomycin. Then, 3D
co-culture in agarose-coated plates of both cell lines with patient-derived PBMCs in a
1:1 ratio was performed as previously described [21]. In some experiments, before the
co-culture, PBMCs from NACT-responders and non-responders were stimulated with
PMA/ionomycin as above described or by T cell receptor (TCR) engagement with mouse
anti-human anti-CD3 (5 µg/mL), anti-CD28 (1 µg/mL), and 5 µg/mL of the crosslinking
antibody rat anti-mouse IgG1 (Biolegend, San Diego, CA, USA). Forty-eight hours after
the start of the co-culture, doxorubicin (Sigma Aldrich, St. Louis, CA, USA) was also
added at 0.1 µg/mL or 0.5 µg/mL, and DMSO was used as a negative control. Four days
after the start of the co-culture (or 48 h after the addition of doxorubicin when used), all
spheroids were removed from the plate, dissociated by pipetting, and stained with the
viability dye to evaluate, by flow cytometry, the percentage of viable cancer cells in the
co-culture. Additionally, the two populations sorted from the healthy donors’ PBMCs,
aforementioned, were cultured separately with MCF-7 spheroids (1:1). This co-culture
was also maintained for 4 days, after which the spheroids were collected, stained, and the
viability of MCF-7 cells in each condition was assessed as described above.
2.5. ELISA
The supernatants from the co-cultures were collected and frozen at −20 ◦C after
centrifugation at 2000 rpm for 10 min. They were used to quantify IFN-γ by ELISA
(Biolegend, San Diego, CA, USA) according to the manufacturer’s instructions. Cytokine
concentration was calculated using the specific standard curves.
2.6. Statistical Analysis
Statistical analysis was performed in GraphPad Prism v6 and SPSS v25 (IBM, Armonk,
NY, USA). Comparison between samples was performed by nonparametric Mann–Whitney
test. To assess the biomarker performance, ROC curves were performed to assign a thresh-
old to divide NACT-responders from non-responders. This cut-off point corresponded to
the maximum of sensitivity and specificity. Univariate and multivariate logistic regressions
were conducted taking into account both cohorts in the same analysis. Progression-free
survival was analyzed by a Kaplan–Meier curve with a log-rank test and hazard ratio
analysis. The probability model was elaborated in R [22]. Statistical significance was
considered for p < 0.05.
3. Results
3.1. Clinical Validation of HLA-DR Level in Cytotoxic T Cells (CTLs) as a Predictive Biomarker of
Response to NACT
The characteristics of the patients selected to performed NACT (1st cohort [9] and 2nd
cohort, flowchart in Figure 1) are described in Table 1.
We have previously observed, in the pilot study with 30 breast cancer (BC) patients
selected for NACT, that HLA-DR level in CTLs was a putative predictive biomarker for
the response to this treatment [9]. Following the REMARK criteria [20], we have enrolled
31 patients in a 2nd independent cohort to validate this biomarker (Figure 2). Response
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to NACT was defined as before [9]. As in the first cohort, in this new cohort, although
the percentage of total CTLs in the biopsies was identical between NACT-responders
and non-responders (Figure 2A), patients with response to NACT had higher expression
of HLA-DR in intratumor CTLs when compared to NACT non-responders (p < 0.0001,
Figure 2B and Figure S2). Then, following the REMARK criteria, we performed a series of
statistical analyses, namely ROC curve and univariate and multivariate regressions.




Figure 2. HLA-DR level in cytotoxic T cells is a clinically validated predictive biomarker of breast cancer patients’ response 
to NACT. (A) Percentage of infiltrating cytotoxic T cells (CTLs) in NACT-responders (black dots, 1st cohort n = 13 and 2nd 
cohort n = 11) and non-responders (red dots, 1st cohort n = 17 and 2nd cohort n = 20) breast cancer patients. (B) HLA-DR 
expression level in CTLs in the same patients as in (A). (C) ROC curve analysis of HLA-DR level in CTLs for the 1st cohort 
(black lines), 2nd cohort (grey lines), and merged cohorts (blue lines). (D) Forest plot of the multivariate analysis per-
formed with both cohorts, including the odds ratio (with 95% confidence interval) and the p-values. (E) Predictive proba-
bility model of response to NACT according to the HLA-DR level in CTLs (merged cohorts). * p < 0.05, ****p < 0.0001. 
3.2. HLA-DR Level in CTLs is also a Prognostic Factor for Breast Cancer 
Since the expression level of HLA-DR in CTLs is related to the activation status of 
these cells, we hypothesized that besides being a predictive biomarker of NACT response, 
it could also be useful as a prognostic factor, related to patients’ clinical outcome. As such, 
we have enrolled both non-NACT and NACT patients and performed a follow-up of 34 
months. Dividing patients with HLA-DRlow CTLs and with HLA-DRhigh CTLs (assessed in 
the biopsies or surgical specimens) according to the threshold value calculated in the ROC 
curve (considering both cohorts, Figure 2C), we observed a significant relationship be-
tween the level of HLA-DR in CTLs and the progression-free survival (PFS) curve (p = 
0.02, Figure 3). Namely, patients with HLA-DRlow CTLs have a lower PFS (hazard ratio 
(HR) = 4.98 (95% CI 1.54–10.31)) when compared to patients with HLA-DRhigh CTLs (HR 
= 0.2 (95% CI 0.1–0.65), Figure 3). Thus, we propose that patients with HLA-DRlow CTLs 
progress or relapse sooner than patients with HLA-DRhigh CTLs, regardless of the treat-
ment. 
A similar analysis was performed for overall survival (OS), but no differences were 
found in this case (data not shown), probably because for OS, a longer follow-up should 
be performed. 
 
Figure 2. HLA-DR level in cytotoxic T cells is a clinically validated predictive biomarker of breast cancer patients’ response
to NACT. (A) Percentage of infiltrating cytotoxic T cells (CTLs) in NACT-responders (black dots, 1st cohort n = 13 and 2nd
cohort n = 11) and non-responders (red dots, 1st cohort n = 17 and 2nd cohort n = 20) breast cancer patients. (B) HLA-DR
expression level in CTLs in the same patients as in (A). (C) ROC curve analysis of HLA-DR level in CTLs for the 1st cohort
(black lines), 2nd cohort (grey lines), and merged cohorts (blue lines). (D) Forest plot of the multivariate analysis performed
with both cohorts, including the odds ratio (with 95% confidence interval) and the p-values. (E) Predictive probability model
of response to NACT according to the HLA-DR level in CTLs (merged cohorts). * p < 0.05, **** p < 0.0001.
ROC curve was executed to determine the cut-off point of HLA-DR level in CTLs to
segregate NACT-responders from non-responders (Figure 2C). In the ROC curve of the
first cohort [9], this value was 8.94, with an area under the curve (AUC) of 0.96, 94.12%
sensitivity, and 100% specificity (Figure 2C). Remarkably, in the ROC curve of the 2nd
cohort, we obtained similar parameters, namely, a threshold value of 8.63, an AUC of 0.91,
80% sensitivity, and 90.91% specificity (Figure 2C), hence, validating our biomarker as a
predict r of response to NACT.
Then, in order to pursue statistical analyses, we poole the data from both co orts.
The r sultant ROC curve had a cut-off value of 9.32, an AUC of 0.95, 91.89% sensitivity,
and 91.67% specificity (Figure 2C), wh c were very strong parameters, thus, corrobo ating
the robustness of HLA-DR level in CTLs to discrimin e NACT-responders from non-
responders.
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By univariate analysis, we observed that the biomarker HLA-DR level in CTLs was
the only significant variable in predicting response to NACT (p < 0.0001, OR = 1.965 (95%
CI 1.35–2.86), Table S1) in a multitude of clinical data and other immunological features
assessed. By multivariate analysis (represented by the forest plot in Figure 2D), we observed
that this biomarker can predict BC patients’ response to NACT (p = 0.01, OR = 1.856 (95%
CI 1.161–2.968)), even when the patients’ age, the BC subtype, and other immunological
parameters of the tumor, such as HLA-DR expression level in Tregs, PD-L1 expression in
tumor cells, and percentage of infiltrating CD4+ and CD8+ T cells, are taken into account.
Since we have previously demonstrated that there was a correlation between the
HLA-DR level in systemic and intratumor CTLs [9], here, we used another cohort of BC
patients (41 non-matched blood samples) and observed that NACT-responders present
higher levels of HLA-DR in circulating CTLs than non-responders (p = 0.03, Figure S3),
supporting the idea that this biomarker is reflected in circulation. Nonetheless, the ROC
curve parameters, in this case, were not so strong as for the intratumor HLA-DR levels in
CTLs (cut-off value of 15.72, AUC of 0.7, 85% of sensitivity, and 52.38% of specificity).
Therefore, anticipating a potential clinical implementation of this biomarker to deter-
mine which patients will benefit from NACT and which should be promptly directed to
surgery (if possible) or to alternative treatments, we have developed a predictive probabil-
ity model, based on the analysis of this biomarker in BC patients’ biopsies (Figure 2E), to





where P(R) is the probability of response, and HLA-DR is the level of this marker in CTLs,
it is possible to assess, in advance, the likelihood of a BC patient to respond to NACT,
considering the biomarker here described.
3.2. HLA-DR Level in CTLs Is Also a Prognostic Factor for Breast Cancer
Since the expression level of HLA-DR in CTLs is related to the activation status of
these cells, we hypothesized that besides being a predictive biomarker of NACT response,
it could also be useful as a prognostic factor, related to patients’ clinical outcome. As
such, we have enrolled both non-NACT and NACT patients and performed a follow-up of
34 months. Dividing patients with HLA-DRlow CTLs and with HLA-DRhigh CTLs (assessed
in the biopsies or surgical specimens) according to the threshold value calculated in the
ROC curve (considering both cohorts, Figure 2C), we observed a significant relationship
between the level of HLA-DR in CTLs and the progression-free survival (PFS) curve
(p = 0.02, Figure 3). Namely, patients with HLA-DRlow CTLs have a lower PFS (hazard
ratio (HR) = 4.98 (95% CI 1.54–10.31)) when compared to patients with HLA-DRhigh CTLs
(HR = 0.2 (95% CI 0.1–0.65), Figure 3). Thus, we propose that patients with HLA-DRlow
CTLs progress or relapse sooner than patients with HLA-DRhigh CTLs, regardless of the
treatment.
A similar analysis was performed for overall survival (OS), but no differences were
found in this case (data not shown), probably because for OS, a longer follow-up should be
performed.
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Figure 3. HLA-DR level in cytotoxic T cells has prognostic value. Progression-free survival of 
breast cancer patients divided in HLA-DR high in cytotoxic T cells (CTLs) (black line, n = 72) and 
HLA-DR low in CTLs (red line, n = 68); this segregation was performed according to the threshold 
value given by the ROC curve with data from both cohorts. 
3.3. HLA-DR+ CTLs Express High Levels of Activation and Proliferation Markers, Release 
Effector Molecules, and are Cytotoxic against Tumor Cells 
To shed some light on the reason why higher levels of HLA-DR in the tumor-infil-
trating CTLs are required for the achievement of a good response to NACT, and eventu-
ally a better prognosis, we tried to better characterize the profile of HLA-DR+ CTLs in 
comparison with HLA-DRnegative CTLs (Figure 4A). By flow cytometry, we observed 
that, when compared to HLA-DRnegative CTLs, HLA-DR+ CTLs were more activated 
(CD69, p < 0.0001), and proliferative cells (Ki67, p < 0.0001) that produced more cytotoxi-
city-related molecules (IFN-γ and Granzyme B, p < 0.0001) showed tissue-residency 
(CD103 and CD39, p < 0.0001) and memory (CD45RO, p < 0.0001) features with similar 
levels of PD-1 and increased expression of Tim3 (p < 0.01). 
Then, and since we demonstrated that in blood from NACT-responders, CTLs also 
exhibit higher levels of HLA-DR than CTLs from NACT non-responders ([9], Figure S3) 
we used patient-derived peripheral blood mononuclear cells (PBMCs) isolated from the 
blood to perform ex vivo assays. 
With the 3D in vitro platform we have developed [21], we added to two different BC 
cell lines (MCF-7 and MDA-MB-231), PBMCs from NACT-responders and non-respond-
ers and assessed the viability of the tumor cells when in contact with patient-derived 
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PBMCs (that are enriched in HLA-DRhigh CTLs (Figure S3)) to the BC 3D-structure reduced 
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Figure 3. HLA-DR level in cytotoxic T cells has prognostic value. Progression-free survival of breast
cancer patients divided in HLA-DR high in cytotoxic T cells (CTLs) (black line, n = 72) and HLA-DR
low in CTLs (red line, n = 68); this segregation was performed according to the threshold value given
by the ROC curve with data from both cohorts.
3.3. HLA-DR+ CTLs Express High Levels of Activation and Proliferation Markers, Release
Effector Molecules, and Are Cytotoxic against Tumor Cells
To shed some light on the reason why higher levels of HLA-DR in the tumor-infiltrating
CTLs are required for the achievement of a good response to NACT, and eventually a better
prognosis, we tried to better c aracterize the profile of HLA-DR+ CTLs in comparison with
HLA-DRnegative CTLs (Figure 4A). By flow cytometry, we observed that, when compared
to HLA-DRnegative CTLs, HLA-DR+ CTLs were more activated (CD69, p < 0.0001), and
proliferative cells (Ki67, p < 0.0001) that produced more cytotoxicity-related molecules
(IFN-γ and Granzyme B, p < 0.0001) showed tissue-residency (CD103 and CD39, p < 0.0001)
and memory (CD45RO, p < 0.0001) features with similar levels of PD-1 and incr ased
expression of Tim3 (p < . 1).
Then, and since we demonstrated that in blood from NACT-responders, CTLs also
exhibit higher lev ls of HLA-DR than CTLs from NACT non-responders ([9], Figure S3)
we used patient-derived peripher l blood m nonuclear cells (PBMCs) isolated from the
blood to perform ex vivo assays.
With the 3D in vitro platform we have developed [21], we added to two different BC
cell lines (MCF-7 and MDA-MB-231), PBMCs from NACT-respon rs and non-r sponders
and assessed the viability of the tumor cells when in contact with patie t-derived PBMCs
(Figure 4B). Interestingly, we noticed that the addition of NACT-responders’ PBMCs (that
are enriched in HLA-DRhigh CTLs (Figure S3)) to the BC 3D-structure reduced their viability
after 4 days in co-culture (p = 0.04 and p = 0.06, Figure 4B); whereas the addition of non-
responders’ PBMCs (that lack HLA-DRhigh CTLs) showed no effect on the viability of the
BC cells (Figure 4B), recapitulating the clinical observations (Figure 2 and Figure S3).
Taking into consideration that HLA-DR+ CTLs are more activated, proliferative, and
produce more cytotoxicity-related molecules (Figure 4A), we hypothesized that HLA-DR+
CTLs indeed exhibit anti-tumor properties and are cytotoxic against tumor cells, unlike
HLA-DRnegative CTLs. To confirm this, we used sorted HLA-DR+ and HLA-DRnegative
CTLs, isolated from the same healthy individuals after stimulation of their PBMCs, and
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cultured them separately with 3D structures of MCF-7 BC cells (Figure 4C). After 4 days in
co-culture, we observed that the BC viability was reduced only in the presence of HLA-DR+
CTLs (p = 0.02, Figure 4C), emphasizing that these cells, and not HLA-DRnegative CTLs,
are cytotoxic against tumor cells.
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of the activation marker CD69, the cytotoxic molecules IFN-γ and Granzyme B (GrzB), the proliferation marker Ki67, the
memory marker CD45RO, the tissu -resid nt markers CD103 and CD39, and the exhaustion markers PD-1 and Tim3 within
the tumor infiltrating population of HLA-DR+ CTLs, normalized to the percentage of these markers within the tumor
infiltrating population of HLA-DRnegative CTLs (number of biopsies used for this characterization is described in the
graph). (B) Percentage of live MCF-7 cells in monoculture (MCF-7, black bar, n = 10), in co-culture with NACT-responders’
PBMCs (MCF-7+R, white bar, n = 10), and with NACT non-responders’ PBMCs (MCF-7+NR, grey bar, n = 11); percentage
of live MDA-MB-231 cells in monoculture (MDA-MB-231, blue bar, n = 11), in co-culture with N CT-responders’ PBMCs
(MDA-MB-231+R, white bar, n = 10), and with NACT non-responders’ PBMCs (MDA-MB-231+NR, grey bar, n = 12). (C)
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and HLA-DRnegative CTLs (black bar, n = 8). Data are represented as mean ± SEM, * p < 0.05, ** p < 0.01, **** p < 0.0001.
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3.4. Stimulation of HLA-DR Level in CTLs Could Increase Their Anti-Tumor Properties
Considering that CTLs expressing a high level of HLA-DR in the tumor microenvi-
ronment (and consequently in the blood) are a prerequisite for NACT success, probably
due to their capacity to decrease the viability of tumor cells, we intended to further explore
the therapeutic potential of these cells, aiming to improve conventional BC treatment.
Therefore, we stimulated patients’ PBMCs to increase HLA-DR in CTLs before adding
these cells to the cancer spheroid. To achieve this stimulation, we used two different
strategies—the canonical PMA/ionomycin stimulation and the TCR engagement. With
both methods, the percentage of HLA-DR+ CTLs increased in both NACT-responders
(p = 0.04 and p = 0.01 for PMA/ionomycin and TCR stimulation, respectively) and non-
responders’ PBMCs (p < 0.0001 and p = 0.0002 for PMA/ionomycin and TCR stimulation,
respectively, Figure 5A and Figure S4). The addition of stimulated PBMCs from non-
responders, to either MCF-7 (p < 0.0001 and p = 0.0003 for PMA/ionomycin and TCR
stimulation, respectively, Figure 5B) or MDA-MB-231 spheroids (p < 0.0001 and p = 0.0001
for PMA/ionomycin and TCR stimulation, respectively, Figure 5D), resulted in a decreased
viability of BC cells, suggesting that ex vivo modulation of PBMCs from non-responders,
with the consequent increase of the numbers of CTLs expressing high levels of HLA-DR,
could indeed ameliorate the anti-tumor ability of these cells.
Additionally, to understand if the combination of chemotherapy and this immune-
modulation is advantageous in the reduction of the BC viability, we used the NACT-agent
doxorubicin. Interestingly, doxorubicin alone did not show a significant impact on tumor
cells viability, especially for the MCF-7 cell line, which could be explained by the higher
chemoresistance of this cell line (Figure 5B,D). Nevertheless, the employment of doxoru-
bicin in combination with non-responders’ PBMCs previously stimulated led to a synergis-
tic reduction on the percentage of live tumor cells (p < 0.0001 for PMA/ionomycin stimula-
tion in both cell lines and p = 0.0002 for TCR stimulation in both cell lines, Figure 5B,D).
Another readout of the anti-tumor ability of the stimulated cells was the concentration
of IFN-γ released to the culture supernatant. Indeed, stimulated PBMCs secrete IFN-γ
(Figure 5C,E), which in the case of TCR engagement, was even similar in non-responders’
PBMCs and in NACT-responders’ PBMCs (Figure 5C,E). It is noteworthy that while non-
stimulated PBMCs of NACT-responders’ produce basal levels of IFN-γ, PBMCs from
non-responder patients did not secrete this cytokine into the culture medium (data not
shown). These results corroborate the idea that it is possible to alter the phenotype of
PBMCs from NACT non-responder patients, therefore, increasing the HLA-DR level in
CTLs but also empowering them with anti-tumor capacity. Hence, stimulation of HLA-DR
in CTLs could have therapeutic potential, as CTLs expressing high level of HLA-DR might
contribute to decrease the resistance of BC tumors to standard treatment.
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TCR stimulation (NR (TCR), black bar, n = 6) after 4 days of co-culture with MCF-7 cells. (D) Viability of MDA-MB-231
cells in co-culture with NACT-responders’ PBMCs (R, white bars, n = 4–10) or with NACT non-responders’ PBMCs (NR,
black bars, n = 6–12) in the presence/absence of doxorubicin (Doxo), with or without previous canonical stimulation
(PMA/ionomycin) and with or without previous TCR stimulation. (E) IFN-γ production of stimulated NACT-responders’
PBMCs with PMA/ionomycin (R (St), white bar, n = 6) or with TCR stimulation (R (TCR), white bar, n = 4); and stimulated
NACT non-responders’ PBMCs with PMA/ionomycin (NR (St), black bar, n = 9) or with TCR stimulation (NR (TCR), black
bar, n = 6) after 4 days of co-culture with MDA-MB-231 cells. Data are represented as mean ± SEM, * p < 0.05, ** p < 0.01, ***
p < 0.001, **** p < 0.0001.
4. Discussion
Biomarkers that can effectively predict breast cancer (BC) patients’ response to neoad-
juvant chemotherapy (NACT) have been widely searched for due to the unmet clinical
need to determine which patients would not benefit from this treatment and should be
promptly directed to more targeted approaches, avoiding the chemotherapy-related toxicity
and the misuse of resources. Tumor-infiltrating lymphocytes (TILs) have been studied
as predictive biomarkers of the response to NACT [23–26]. However, TILs assessment
is still not used in the clinical routine, despite an international effort to standardize the
evaluation of this biomarker [27]. The main disadvantage of the employment of TILs is
the fact that they are presented as a single population, though they comprise immune cells
with opposite roles (pro- and anti-tumor T cells). Indeed, TILs represent a heterogeneous
population, including the immunosuppressive regulatory T cells. Additionally, tumors
can escape the immune system through, for instance, the release of anti-inflammatory
cytokines (such as IL-10 or TGF-β) or the activation of immune checkpoints, namely, the
PD-1/PD-L1 axis, which will prevent the activation of CTLs and, consequently, lower their
cytotoxic function. Only when these escape mechanisms are not yet engaged can CTLs
become activated by recognizing tumor antigens and produce effector molecules, such as
Perforin and Granzyme B, that lead to tumor cell elimination. Moreover, TILs have been
suggested mainly for TNBC patients (excluding the majority of BC cases); its analysis is
based on immunohistochemistry (IHC) of a single tumor plane, excluding the whole 3D
conformation, and similarly, TIL scoring is more subjective.
To overcome the limitations of TILs, we previously proposed [9] and validated in the
current study a new biomarker—HLA-DR level in CTLs, which accurately discriminates
NACT-responders from non-responders and better reflects the overall immune status of
the tumor microenvironment. Actually, HLA-DR+ CTLs found in the biopsies represent
a population of activated CTLs, as HLA-DR per se is an activation marker of T lympho-
cytes [13] but also expresses more of other activation markers (e.g., CD69) when compared
with HLA-DRnegative CTLs. This subset also has higher proliferative capacity, more
tissue-residency and memory markers (which have been highlighted as an interesting
anti-tumor phenotype [28]), a similar level of exhaustion, and notably, increased cytotoxic
properties against tumor cells (as observed in the 3D co-cultures) when compared to other
CTLs present in the tumor microenvironment. Thus, we verified, in two independent
cohorts, that HLA-DR level in CTLs is, statistically, by the ROC curve parameters and the
univariate and multivariate analysis of the merged data, a powerful predictive factor to
segregate BC patients that will or will not respond to NACT. Additionally, this biomarker
is independent of the BC subtype and other clinical parameters, such as the patients’ age,
reflecting the capacity to be used in all BC patients that would be, based on the current
criteria, selected to receive NACT.
Here, we proposed the assessment of HLA-DR expression level in CTLs by flow
cytometry and validated its determination in the following conditions: biopsies should
be collected in Transfix (to preserve cellular antigens), processed, and stained using a
combination of two monoclonal mouse anti-human antibodies, specifically anti-CD8-PE
(clone HIT8a) and anti-HLA-DR-APC (clone L243) from Biolegend in a 1:50 concentration.
The flow cytometry analysis should be performed by gating HLA-DR within the CD8+
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population (CTLs), and the value HLA-DR level in CTLs was obtained by determining
the ratio between the median fluorescence intensity (MFI) of HLA-DR+ and the MFI of
HLA-DRnegative population, as we previously reported [9]. The employment of flow
cytometry could be an advantage because we cannot distinguish intratumor CTLs from
stromal CTLs, as it is possible with IHC; hence, this technique is more representative of the
whole biopsy than IHC, where only a slice of the 3D structure of the biopsy is used. Actually,
several reports claim that stromal TILs are more important than the tumor-infiltrating ones
to predict response to NACT (reviewed in [29]), while others report the opposite [30].
With flow cytometry, we can quantify both simultaneously. Nevertheless, flow cytometry
is not as widely available in pathology departments of hospitals and clinics as IHC is,
which might represent a limitation. Another advantage of the proposed biomarker is
its systemic reflection, as NACT-responders also have higher expression of HLA-DR in
blood CTLs then non-responders. Nonetheless, the parameters of the ROC curve using
blood samples were not as noticeable as for the biopsies; hence, the prediction of NACT
response should be assessed in the tissue biopsies. However, blood analysis could be
useful as a complement and/or can be performed, for instance, to monitor NACT efficiency
throughout the treatment.
Envisioning the application of this biomarker in a clinical setting, we have developed
a probability model that can be used by clinicians in the therapeutic decision process.
Based on this model, we suggest segregating patients into three groups—high probability
of response to NACT (>60% that corresponds to an HLA-DR level higher than 10.8),
intermediate probability of response (20–59% that corresponds to an HLA-DR between
8 and 10.8), and low probability of response (<20% that corresponds to an HLA-DR
level lower than 8). This stratification should help to guarantee that patients with high
probability of response to NACT will be submitted to this treatment, while patients with low
probability of response to NACT will be promptly directed to surgery/alternative therapies
whenever possible. Of course, for the cases of patients with intermediate probability
of response, the therapeutic decision would be more challenging, and clinicians should
analyze it case-by-case and contemplate different aspects, such as if another therapeutic
option is available or if NACT is still the best option. It is noteworthy that the equation
presented was extrapolated from the results of these studies, using both cohorts merged,
so it is only valid for HLA-DR level in CTLs ranging from 4.13 to 24.63 when determined
as we did.
In addition to being a predictive factor, HLA-DR level in CTLs is also associated
with the progression-free survival curve considering 34 months of follow-up of all the
patients whose biopsies/surgical specimens we analyzed, independently of the treatment
performed. This observation suggests that besides the predictive value of this biomarker
for the response to a specific treatment, it has also a promising prognostic value that could
be useful to determine, in advance, BC patients’ outcome.
Recently, we have developed a 3D platform composed of BC cell lines and PBMCs [21],
anticipating the use of this system as a patient-customized drug screening assay. Here, we
took advantage of this 3D system to demonstrate in vitro that only PBMCs from NACT-
responders have the ability to reduce the viability of tumor cells. Given the fact that
HLA-DR expression is boosted in circulating CTLs from NACT-responder patients, we
further showed that it is this subset, and not other CTLs, that in fact are responsible for the
anti-tumor properties of NACT-responders’ PBMCs. In line with the idea that an immune
status favoring cytotoxicity against tumors will determine the success of chemotherapy
by allowing the control of chemotherapy-resistant cancer cells, these results contribute to
explain the requirement of CTLs expressing high levels of HLA-DR for NACT efficacy and
a good outcome, corroborating clinical observations.
The identification of patients who most likely will not respond to NACT is critical to
promptly direct them for alternative and/or individualized treatments, although, so far,
these treatments are still scarce. Given the observation that CTLs with enhanced expression
of HLA-DR have anti-tumor properties and are important for NACT success, to tackle
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this issue, we used our 3D co-culture assay also to investigate the therapeutic potential of
these cells. Excitingly, the results showed that the stimulation of NACT non-responders’
immune cells raises HLA-DR level at the surface of their CTLs and, therefore, increases
the ability of these cells to reduce the viability of cancer cells in culture. This effect was
even more pronounced when stimulated immune cells were added to the cancer cells
in the presence of doxorubicin, suggesting that the upsurge of HLA-DR level in CTLs,
especially of NACT non-responders, could be a promising therapeutic strategy to combine
with chemotherapeutic agents to ameliorate BC treatments.
5. Conclusions
NACT is a widely accepted therapeutic option for patients with locally advanced
BC. However, in patients with chemotherapy-resistant tumors, it is not efficient and, in
some cases, leads to even more severe forms of the disease. Here, we validated, in an
independent cohort, HLA-DR level in CTLs as a simple and robust biomarker to determine
the likelihood of tumor remission after NACT and developed a predictive probability model
foreseeing its implementation in the clinical routine. This biomarker also has the potential
to be used in clinical trial design to evaluate highly expensive and technically demanding
immunotherapies, particularly in those BC patients who might truly need/take advantage
of these novel treatments. In the future, it may be also adapted as a predictive/prognostic
factor for other types of cancer.
The lack of alternative therapeutic options for BC patients with modest response to
conventional treatments is another obstacle that needs to be circumvented. Actually, the
discovery of new predictive biomarkers should go hand-in-hand with the development
of new treatments, to be able to offer to patients that will not respond to conventional
therapies. Thus, here, we also showed that it is possible to modulate the expression of
HLA-DR in CTLs and, consequently, improve the ability of these cells to kill tumor cells
in culture, opening new therapeutic possibilities based on these cells. Nonetheless, more
clinical grade immune-modulators to increment HLA-DR in patients’ CTLs should be
further explored to translate this approach for BC patients and improve the management
of this disease.
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lymphocytes (CTLs) of NACT-responders (R, black dots, n = 21) and NACT non-responders (NR, red
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PBMCs isolated from breast cancer patients with or without previous PMA/ionomycin stimulation.
Table S1: Univariate analysis for the biomarker HLA-DR level in CTLs. HLA-DR expression level
in CTLs and other immunological markers and clinical parameters were analyzed by univariate
analysis. p-value, odds ratio and the confidence interval of the odds ratio are represented.
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